Image-guided solid tumor ablation methods have significantly advanced in their capability to target primary and metastatic tumors. These techniques involve noninvasive or percutaneous insertion of applicators to induce thermal, electrochemical, or mechanical stress on malignant tissue to cause tissue destruction and apoptosis of the tumor margins. Ablation offers substantially lower risks compared to traditional methods. Benefits include shorter recovery periods, reduced bleeding, and greater preservation of organ parenchyma compared to surgical intervention. Due to the reduced morbidity and mortality, image-guided tumor ablation offers new opportunities for treatment in cancer patients who are not candidates for resection. Currently, image-guided ablation techniques are utilized for treating primary and metastatic tumors in various organs with both curative and palliative intent, including the liver, pancreas, kidneys, thyroid, parathyroid, prostate, lung, breast, bone, and soft tissue. The invention of new equipment and techniques is expanding the criteria of eligible patients for therapy, as now larger and more high-risk tumors near critical structures can be ablated. This article provides an overview of the different imaging modalities, noninvasive, and percutaneous ablation techniques available and discusses their applications and associated complications across various organs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11274819 | PMC |
http://dx.doi.org/10.3390/cancers16142560 | DOI Listing |
Kardiochir Torakochirurgia Pol
December 2024
Department of Surgery, General University Hospital of Patras, Patras, Greece.
J Clin Med
December 2024
Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
The standard of care for early-stage NSCLC has historically been surgical resection. Given the association of lung cancer with smoking, a large number of early-stage patients also have active smoking-related medical comorbidities such as COPD precluding surgery. The current approach for treating such inoperable patients is frequently considered to be stereotactic body radiation therapy (SBRT).
View Article and Find Full Text PDFJ Am Chem Soc
January 2025
Center for AIE Research, Guangdong Provincial Key Laboratory of New Energy Materials Service Safety, College of Materials Science and Engineering, Shenzhen University, Shenzhen 518060, P. R. China.
Developing small organic molecular phototheranostic agents with second near-infrared (NIR-II) aggregation-induced emission (AIE) is paramount for the phototriggered diagnostic imaging and synchronous in situ therapy of cancer via an excellent balance of the excited states energy dissipations. In this study, a multifunctional iridium(III) complex is exploited by the coordination of an AIE-active N^N ancillary ligand with a trivalent iridium ion. The resultant complex DPTPzIr significantly outperforms its parent ligand in terms of absorption/emission wavelengths, reactive oxygen species (ROS) production, and photothermal conversion, which simultaneously endow DPTPzIr nanoparticles with matched absorption peak to commercial 808 nm laser, the longest NIR-II emission peak (above 1100 nm) among those previously reported AIE iridium(III) complexes, potentiated type-I ROS generation, and as high as 60.
View Article and Find Full Text PDFRecent Adv Drug Deliv Formul
December 2024
Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Pharmaceutics, Gujarat, India.
The development of precise and reliable cancer treatments has been a long-standing goal in oncology. Conventional therapies often affect healthy tissues, leading to significant side effects. To overcome these challenges, researchers are exploring new methodologies that combine advanced drug delivery systems with state-of-the-art imaging technologies to target tumors more effectively.
View Article and Find Full Text PDFOper Orthop Traumatol
December 2024
Department for Orthopaedic and Trauma Surgery, Lucerne Cantonal Hospital LUKS, Spitalstrasse, Lucerne, Switzerland.
Objective: To maximize local tumor control, stabilize affected bones, and preserve or replace joints with minimal interventional burden, thereby enhancing quality of life for empowered living.
Indications: Suitable for patients with bone metastases, particularly those with severe pain and/or fractures and appropriate life expectancy.
Contraindications: In primary bone tumors, refer to the sarcoma surgery team for evaluation of wide resection.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!